These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 31580249)

  • 1. Integrative Exome Sequencing Analysis in Castration-Resistant Prostate Cancer in Chinese Population.
    Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
    Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
    Ercolani C; Di Benedetto A; Terrenato I; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Buglioni S; Ramieri MT; Mentuccia L; Gamucci T; Perracchio L; Pescarmona E; Mottolese M; Barba M; Vici P; De Maria R; Maugeri-Saccà M
    Cancer Biol Ther; 2017 May; 18(5):339-346. PubMed ID: 28387539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
    Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
    J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
    Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
    Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
    Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
    Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
    Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mst1 deletion attenuates renal ischaemia-reperfusion injury: The role of microtubule cytoskeleton dynamics, mitochondrial fission and the GSK3β-p53 signalling pathway.
    Li H; Feng J; Zhang Y; Feng J; Wang Q; Zhao S; Meng P; Li J
    Redox Biol; 2019 Jan; 20():261-274. PubMed ID: 30384260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A breakdown of the Hippo pathway in gastric cancer.
    Xu ZP; Zhu JS; Zhang Q; Wang XY
    Hepatogastroenterology; 2011; 58(110-111):1611-7. PubMed ID: 21940329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer.
    Wu F; Ning H; Sun Y; Wu H; Lyu J
    Aging Male; 2023 Dec; 26(1):2183947. PubMed ID: 36974949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
    Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
    Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
    Wang Z; Yan X; Tang P; Tang T; Wang Y; Peng S; Wang S; Lan W; Wang L; Zhang Y; Zhang J; Li K; Shu Z; Xu J; Qin J; Zhang D; Jiang J; Liu Q
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):180-187. PubMed ID: 36401126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.
    Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N
    Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
    Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W
    Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
    Van Allen EM; Foye A; Wagle N; Kim W; Carter SL; McKenna A; Simko JP; Garraway LA; Febbo PG
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):23-7. PubMed ID: 24366412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.